[1] Yoo JJ, Kim SG.HVPG as a predictor of mortality in non-critically-ill cirrhotic patients. J Korean Med Sci, 2019, 34(33): e235.
[2] Sarin SK, Kumar A, Chawla YK, et al.Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int, 2007, 1(3): 398-413.
[3] Schouten JN, Nevens F, Hansen B, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther, 2012, 35(12): 1424-33.
[4] Agarwal S, Sharma S, Anand A, et al. Liver stiffness assessment as an alternative to hepatic venous pressure gradient for predicting rebleed after acute variceal bleed: a proof-of-concept study. JGH Open, 2021, 5(1): 73-80.
[5] 中华医学会超声医学分会, 中国研究型医院学会肿瘤介入专业委员会, 国家卫生和健康委员会能力建设和继续教育中心超声医学专家委员会.门静脉高压诊断标准.中华肝脏病杂志, 2021, 29(5): 385-402.
[6] European Association for the Study of the Liver. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update. J Hepatol, 2021, 75(3): 659-689.
[7] Ru N, He CH, Ren XL, et al. Risk factors for sinistral portal hypertension and related variceal bleeding in patients with chronic pancreatitis. J Dig Dis, 2020, 21(8): 468-474.
[8] Li H,Yang Z, Tian F. Clinical characteristics and risk factors for sinistral portal hypertension associated with moderate and severe acute pancreatitis: a seven-year single-center retrospective study. Med Sci Monit, 2019, 25:5969-5976.
[9] Yu C, Ding L, Jiang M, et al. Dynamic changes and nomogram prediction for sinistral portal hypertension in moderate and severe acute pancreatitis. Front Med (Lausanne), 2022, 9: 875263.
[10] 杜奕奇,宋英晓. 胰源性门静脉高压的诊断与处理. 中华消化杂志, 2020, 40(7): 450-453.
[11] Khanna R, Sarin SK. Idiopathic portal hypertension and extrahepatic portal venous obstruction. Hepatol Int, 2018, 12(Suppl 1): 148-167.
[12] Abu-Hilal M, Tawaker J. Portal hypertension secondary to myelofibrosis with myeloid metaplasia: a study of 13 cases. World J Gastroenterol, 2009, 15(25): 3128-3133.
[13] Alvarez-Larran A, Abraldes JG, Cervantes F, et al. Portal hypertension secondary to myelofibrosis: a study of three cases. Am J Gastroenterol, 2005, 100(10): 2355-2358.
[14] 赵剑波,谭卿. 非肝硬化性门静脉高压症研究进展. 实用肝脏病杂志, 2021, 24(5): 613-616.
[15] Elkrief L, Houssel-Debry P, Ackermann O, et al. Portal cavernoma or chronic non cirrhotic extrahepatic portal vein obstruction. Clin Res Hepatol Gastroenterol, 2020, 44(4): 491-496.
[16] Khanna R, Sarin SK. Non-cirrhotic portal hypertension - diagnosis and management. J Hepatol, 2014, 60(2): 421-441.
[17] 张誉,杨永峰. 特发性非硬化性门静脉高压诊治进展. 中华肝脏病杂志, 2021,29(1):87-91.
[18] Schouten JN, Verheij J, Seijo S. Idiopathic non-cirrhotic portal hypertension: a review. Orphanet J Rare Dis, 2015, 10: 67.
[19] 何福亮, 马琳, 李悦榕, 等. 非肝硬化性门脉高压的临床诊断. 实用肝脏病杂志, 2022, 25(1): 1-4.
[20] 陈功海, 王广川, 张春清. 特发性非肝硬化门静脉高压症诊治进展. 中华消化病与影像杂志(电子版), 2021, 11(3): 132-138.
[21] Hernandez-Gea V, Gottardi AD, Leebeek FWG, et al. Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. J Hepatol, 2019, 71(1): 175-199.
[22] Gavriilidis P, Marangoni G, Ahmad J, et al. State of the art, current perspectives, and controversies of Budd-Chiari syndrome: a review. J Clin Med Res, 2022, 14(4): 147-157.
[23] Iliescu L, Toma L, Mercan-Stanciu A, et al. Budd-Chiari syndrome - various etiologies and imagistic findings, a pictorial review. Med Ultrason, 2019, 21(3):344-348.
[24] Akhan O, Karaosmanoglu AD, Ergen B. Imaging findings in congenital hepatic fibrosis. Eur J Radiol, 2007, 61(1): 18-24.
[25] Lee H, Rehman AU, Fiel MI. Idiopathic noncirrhotic portal hypertension: an appraisal. J Pathol Transl Med, 2016, 50(1): 17-25. |